Skip to content

EBIT at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.11M+30.9%
Pfizer logo
PfizerPFE
Merck & Co. logo
Merck & Co.MRK
AbbVie logo
AbbVieABBV
Insmed logo
InsmedINSM
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Calculated from Innoviva, Inc.’s reported figures.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s EBIT?
Innoviva, Inc. (INVA) reported EBIT of $38.15M in Q1 2026.
How has Innoviva, Inc.'s EBIT changed year-over-year?
Innoviva, Inc.'s EBIT decreased by 7.9% year-over-year, from $41.43M to $38.15M.
What is the long-term trend for Innoviva, Inc.'s EBIT?
Over 3 years (2021 to 2025), Innoviva, Inc.'s EBIT has grown at a -24.1% compound annual growth rate (CAGR), from $375.1M to $163.75M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.